However, glucagon-like peptide 1 receptor agonists (GLP1-RAs), which were recently developed as a T2DM treatment drug, has been confirmed to have a strong weight control effect as well as a CVD prevention effect [14]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.